Coherus BioSciences Inc
NASDAQ:CHRS
Coherus BioSciences Inc
NASDAQ:CHRS
Price:
2.235 USD
-1.54%
Market Closed
Updated:
May 6, 2024
Coherus BioSciences Inc
Cash from Financing Activities
|
Coherus BioSciences Inc
Cash from Financing Activities Peer Comparison
Comparables:
ABBV
GILD
AMGN
VRTX
REGN
Competitive Cash from Financing Activities Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Cash from Financing Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Coherus BioSciences Inc
NASDAQ:CHRS
|
Cash from Financing Activities
$69.6m
|
CAGR 3-Years
-32%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
21%
|
|
|
Abbvie Inc
NYSE:ABBV
|
Cash from Financing Activities
-$17.2B
|
CAGR 3-Years
-14%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
-17%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Cash from Financing Activities
-$5.1B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
9%
|
CAGR 10-Years
N/A
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Cash from Financing Activities
$21B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
23%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Cash from Financing Activities
-$562.2m
|
CAGR 3-Years
-4%
|
CAGR 5-Years
-51%
|
CAGR 10-Years
N/A
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Cash from Financing Activities
-$1.8B
|
CAGR 3-Years
3%
|
CAGR 5-Years
-88%
|
CAGR 10-Years
N/A
|
See Also
What is Coherus BioSciences Inc's Cash from Financing Activities?
Cash from Financing Activities
69.6m
USD
69.6m
USD
Based on the financial report for Dec 31, 2023, Coherus BioSciences Inc's Cash from Financing Activities amounts to 69.6m USD.
What is Coherus BioSciences Inc's Cash from Financing Activities growth rate?
Cash from Financing Activities CAGR 10Y
21%
21%
Over the last year, the Cash from Financing Activities growth was 28%. The average annual Cash from Financing Activities growth rates for Coherus BioSciences Inc have been -32% over the past three years , -8% over the past five years , and 21% over the past ten years .
You don't have any saved screeners yet
